Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial

Annika Malmström*, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E. Hegi, Johan Rosell, Roger Henriksson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

666 Scopus citations

Fingerprint Dive into the research topics of 'Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences